Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,723 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Denfivontinib activates effector T-cells through NLRP3-inflammasome, yielding potent anticancer effects by combination with pembrolizumab.
Kim DK, Synn CB, Lee W, Jo HN, Lee CY, Lee S, Hwang JY, Kim Y, Kang SS, Baek S, Na K, Yang SM, Kim MH, Han H, Han YJ, Kim JH, Park SY, Park YJ, Lee GT, Choi SJ, Sohn JO, Ye SK, Lee JB, Lim SM, Hong MH, Pyo KH, Cho BC. Kim DK, et al. Among authors: baek s. Mol Cancer Ther. 2024 Dec 5. doi: 10.1158/1535-7163.MCT-24-0501. Online ahead of print. Mol Cancer Ther. 2024. PMID: 39632711
Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma.
Lim SM, Kang SS, Kim DK, Lee SH, Synn CB, Baek S, Yang SM, Han YJ, Kim MH, Han H, Na K, Kim YT, Yun MR, Kim JH, Byeon Y, Kim YS, Lee JB, Hong MH, Curtin JC, Patel B, Bergiers I, Pyo KH, Cho BC. Lim SM, et al. Among authors: baek s. Cancer Res Commun. 2024 Jul 1;4(7):1748-1764. doi: 10.1158/2767-9764.CRC-24-0107. Cancer Res Commun. 2024. PMID: 38916448 Free PMC article.
YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment.
Kim DK, Synn CB, Yang SM, Kang S, Baek S, Oh SW, Lee GJ, Kang HW, Lee YS, Park JS, Kim JH, Byeon Y, Kim YS, Lee DJ, Kim HW, Park JD, Lee SS, Lee JY, Lee JB, Kim CG, Hong MH, Lim SM, Kim HR, Pyo KH, Cho BC. Kim DK, et al. Among authors: baek s. Front Chem. 2022 Dec 5;10:998013. doi: 10.3389/fchem.2022.998013. eCollection 2022. Front Chem. 2022. PMID: 36545214 Free PMC article.
CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production.
Na K, Lee S, Kim DK, Kim YS, Hwang JY, Kang SS, Baek S, Lee CY, Yang SM, Han YJ, Kim MH, Han H, Kim Y, Kim JH, Jeon S, Byeon Y, Lee JB, Lim SM, Hong MH, Pyo KH, Cho BC. Na K, et al. Among authors: baek s. Front Immunol. 2024 Mar 7;15:1336246. doi: 10.3389/fimmu.2024.1336246. eCollection 2024. Front Immunol. 2024. PMID: 38515751 Free PMC article.
Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types.
Kim DK, Lee CY, Han YJ, Park SY, Han H, Na K, Kim MH, Yang SM, Baek S, Kim Y, Hwang JY, Lee S, Kang SS, Hong MH, Lim SM, Lee JB, Kim JH, Cho BC, Pyo KH. Kim DK, et al. Among authors: baek s. Front Immunol. 2024 Apr 12;15:1330228. doi: 10.3389/fimmu.2024.1330228. eCollection 2024. Front Immunol. 2024. PMID: 38680496 Free PMC article.
4,723 results